SRSEC Reporting Desk

Aprea Therapeutics, Inc. (APRE) – Company response

2026-03-16 · Re: (the “Company”) Registration Statement on Form S-3 Filed February 20, 2026 · Accession 0001104659-26-028073 · Explained / pushed back

Financial Statement Requirements (Reg S-X)

2026-03-16 · (the “Company”) Registration Statement on Form S-3 Filed February 20, 2026 · Comment 1 · Staff Comment Explained / pushed back
Staff comment: We note that you filed this registration statement more than 45 days after the end of your fiscal year. As such, you do not appear to meet the age of financial statement requirements of Rule 8-08(b) of Regulation S-X. Please revise to include audited financial statements for the fiscal year ended December 31, 2025. letter →
Company response: The Company respectfully advises the Staff that the Company has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 16, 2026. As a result, the audited financial statements for the fiscal year ended December 31, 2025, are now on file with the Commission and incorporated by reference into the Registration Statement in accordance with the incorporation by reference provisions of the Registration Statement. The Company respectfully believes that the filing of the Form 10-K addresses the Staff’s comment. The Company acknowledges the Staff may have further questions and will respond promptly to any additional comments. Please do not hesitate to contact the… response letter →
Financial Statement Requirements (Reg S-X)

Full letter on EDGAR → · Filing index · All Aprea Therapeutics, Inc. (APRE) correspondence

Financial Statement Requirements (Reg S-X) – what to check:

Templates & resources

Listed alphabetically by provider. Listings are not endorsements; no provider pays for placement. All templates & resources